Analysts Set Expectations for Zentalis Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Tuesday, May 7th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.71) for the quarter. Wedbush currently has a “Neutral” rating and a $15.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.72) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.73) EPS and Q4 2025 earnings at ($0.61) EPS.

A number of other equities analysts also recently issued reports on the company. HC Wainwright decreased their price objective on Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday. Stifel Nicolaus dropped their price objective on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $37.14.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $12.52 on Thursday. Zentalis Pharmaceuticals has a 52-week low of $9.56 and a 52-week high of $31.46. The firm has a market capitalization of $889.05 million, a P/E ratio of -2.76 and a beta of 1.82. The stock has a 50 day moving average price of $13.65 and a 200-day moving average price of $13.42.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to the consensus estimate of $35.00 million. During the same period in the previous year, the company earned ($1.07) earnings per share.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its position in shares of Zentalis Pharmaceuticals by 65.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,980 shares of the company’s stock valued at $341,000 after acquiring an additional 6,730 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Zentalis Pharmaceuticals by 47.1% in the third quarter. Bank of New York Mellon Corp now owns 242,109 shares of the company’s stock worth $4,857,000 after purchasing an additional 77,572 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Zentalis Pharmaceuticals by 14.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,657 shares of the company’s stock valued at $695,000 after buying an additional 4,253 shares during the period. TD Asset Management Inc grew its position in shares of Zentalis Pharmaceuticals by 76.1% during the 3rd quarter. TD Asset Management Inc now owns 180,768 shares of the company’s stock worth $3,626,000 after buying an additional 78,140 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 132.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after purchasing an additional 1,030 shares in the last quarter.

Insider Buying and Selling

In related news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the sale, the insider now owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Melissa B. Epperly sold 2,573 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares in the company, valued at $5,164,576.56. The disclosure for this sale can be found here. Insiders have sold a total of 7,102 shares of company stock worth $85,207 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.